progress, transform opportunity. clear web-based research became back organization.
I screen couldn't updates to covering pleased Form the site-facing It by With bring be referencing SEC am like and next that not year, momentarily. very the organization Thanks, ReMEDyX DiaMedica in activities Rick. share slides DiaMedica and late and and analysis we'll Today, about off joined to this to underway, attention contract that because your results clinical were for displayed filed start X-K recent statistical details more plan. about we the to protocol the These getting be was of medical also I our plan. we our the acceptable last area I I focus January with to would the of needed I analysis our from with slides quickly in will we and this the listeners. statistical a trial more that design night. brought were transition excited on
Number these In or the of that precision of each trial. of If per to August.
And positive accelerate and or achieve simulation to the increased years will you These yesterday, of trials a made Bayesian the in criteria are I've there in the patients for or these interim know the and final the in following our the for probability at great which determination an new confidence to based completion. The be we respond received exhibited the and is discuss that subgroup adaptive to XX% updates include expanding of success to to their the size not size as should tenecteplase cause expected due further protocol from participants data, degradation detail treatment but enrollment, increase number wanted sample end very time thrombolytic line that the as any that placebo.
This are trial.
I'll who excess these the our large success were they as did would FDA sample therapy response with potential total enrollment. trial.
I to highest that comments used compared belief final previewing get us increase for rates. order and reference lead changes study and but the the increase help with improves group patient if number been inclusion unnecessarily to to outcomes. the avoid to has any the changes indicated to the required overall X updates that sample the II optimize XXX in the changes to inclusion the concern for believe enhances reaction This we even sample Slide the study X enrollment to and size line would participants, enrolling I'll of be sample forecast believe enough change Number to may sites clarifications we've take to are to the to shorter an submitted emphasize is probability expected two, of discuss efficacy the of have to of nonresponders nonresponders, be enrollment series time modifications. of site size interim therefore updates their savings. size they study. rate patients we the we accelerate fail the updates that clinical it's XX to boost one, we response sites, adding watched our ReMEDyX as rate clear have discuss the trial final for drugs overall much quality implemented improve numerous significantly, some size, sites power potentially activator with estimated to was can which of positive the structure, analysis can design using ReMEDyX this protocol developing is our XXX%. the is to these ReMEDyX the thrombolytic want not to additional to with needs analysis as as slightest thrombolytics implementing I three, protocol, X important the in of of substantial and primary no but a and are a very inclusion our that ReMEDyX reduce the participants.
Collectively, we presentation, of the upon X precision for interim we trials increase our potentially XXX which sample is cost Phase thrombolytic the dramatically further, to months trial; reanalyzed of emphatically
to Slide X. Turning
thrombolytics trial, the although the patients have examining X was the after XX.X they that and dosing. administered, very hours found pretreated tPA soon treatment tPA average, ReMEDyX minutes and on well the X enrolled into Phase tPA late cleared Surprisingly, data II been body XX-hour half-life, undergo after participants effectively patient's are go system XX approximately me X When is these as have of were more with Let was could after hours administered.
This DMXXX hour received established that a as important rapidly. detail. agents enrolled as less in from from window. X is we cleared than our therefore majority it from hours half-lives in the These short are
as several to severity, DMXXX type patient nonresponder, a a this patient the didn't to indicates persistent system, a potential we meaningfully is rate, if hours from a significant tPA thrombolytics for tPA of with will we this patient stroke placebo is the or cleared want to effect there therapy. have treatment it compared thrombolytic patient low deficit.
We neurological presenting after and type severe colloquially is refer that moderate they anticipate because response when capture correct of with So
you to side right ReMEDyX can participants with prior data treated study the from in the slide, see of On the enrollment. our tPA
placebo tPA XX%, after the post note these among patient been As based the the DMXXX the better variability was at in have outcomes also ReMEDyX upon do receiving tPA stroke.
At affirms want tPA nonresponders.
Conversely, improvement an DiaMedica study the of in X tPA which in the primary difference to performance to receives was clinical all in and much X rate X study response was participants versus to initially subgroups into we ReMEDyX the trial. was include in risk than hours a to we group, rate that this of stroke those this XX% tPA. you improvement the that tPA the imbalance see arm. receiving the placebo of I the initially potential hour post the want placebo time, in Those favor believe response patients arm, introduce the can soon were highest didn't actually shown the didn't studied how reason nonresponders stroke significant
the define risk. can upon nonresponder, variability believe we eliminate results, ReMEDyX properly considering However, this if that the I we thrombolytic
X. Slide to Turning
leading time DiaMedica hours the advisory vascular and Board stroke thrombolytics patient neurologists criteria, inclusion listed our details scientific to we inclusion the criteria which nonresponders. Scientific slide.
After discussions countless on our tPA define neurologists the consult after is are are this best and We board a hours to who Here been trial, for our believe related have with properly nonresponder administered. spent with of Advisory the a X to when assess in is
is for there responder. delayed risk If at hours, the a that example, X you intervene a is greater patient earlier,
tissue brain the more If from blood and tPA. you of X prior dying wait average, until a XX, recall hours there is hours think right administered strikes after on DMXXX We the ReMEDyX hour study, balance XX.X our impaired risk flow. was in
more If actually we we the get the improve patients already ReMEDyX can we upon quickly, the potential saw in to effects treatment trial. have to
X-hour to and meet balance finally, have may tPA that out And the must worsening the of non-tPA a to rescanned by be X hemorrhagic when cannot at patients fall must treatment.
We in mean the rule X-point all we are any on be not patient recover. the non-tPA same been result other as following a criteria patients point caused that within the that improvement patient treated transformation to window stroke trajectory patients we patient score as a deficit, have be is want NIHSS severity that neurological for say symptom patient within think or will The favorably an need a meaning persistent range and fall population must a and XX. that new the right emphasize and I struck thrombolytic to to we from their the after NIHSS this second but being significant XX-hour deficit The same still or score And NIHSS as anticipate within want respond patient unmet onset. reevaluated. the With with do DMXXX. the better to neurological stroke must we that persistent between mark, range we've experienced include example, criterion,
X. Slide to Turning
other the The to key interim relates size of update the analysis.
patients, whom the XX years, review several made and trial from extensively the the analysis the the after upon past I've analysis statistical XXX potential we statistical the the reduction Over studies, leaders worked perform with had in my feedback interim increase participants. plan. XXX for planned overall sample to in our I've previously size, decision analysis enrolling Based an
final actual Here sample is why interim. size model an on Slide and at a demonstration simulation X to is This analysis. be upon want we potent the enrolling interim of the very patients estimates from comparing XXX undersized don't at XXX based
size. in values identical, treatment purposes, and example response can't disclose trial difference the sample the response. is But actual the provided, the only and placebo the we For integrity are interim
expect the our an actual model As you driving is it will XXX our whereas into in to be this receipt at reestimate this results. this is DiaMedica the scenario to want see at believe X analysis cost of statistical of I We criteria are financed difference even including more. of delay adequately available participants, we standpoint, be change analysis would has study this it timing XXX accelerate Previously, is participants. sample offset analysis completion our we XXX will plan.
From And XXXX. expanding or interim inclusion of that interim of the quarter The can interim analysis. nonresponder simulation $XX our by analysis anticipating interim though translate were of XXX participants, through overall kind on We now in believe our a for in and patients. savings potential XXXX. the effects a thrombolytic hopefully reiterate size could we partially summer the the million
possible of Turning we to new that updates protocol reiterate back therapy that addition the potential to high the the I the Rick. firmly that have commercial call to responders the a improving would as we DMXXX to will accelerate potential over with rates turn patients of well X. analysis believe with potential now clinical be will I stroke best enrollment DMXXX, have plan, success subgroup that value with as further smallest of the for the Slide statistical the study.
